Recurrent severe diarrhea with acute kidney injury after drug reinitiation highlights a rare but serious enteropathy linked ...

A gastroenterologist at the Mayo Clinic has uncovered a rare but potentially serious association between the angiotensin II receptor antagonist (ARB) olmesartan and severe gastrointestinal problems ...

BETHESDA, MD – The US Food and Drug Administration (FDA) has completed its safety review of olmesartan (Benicar, Daiichi Sankyo) in diabetic patients, stating there is no clear evidence of increased ...

Olmesartan Medoxomil is indicated for the treatment of high blood pressure or hypertension. It was developed by the Japanese pharmaceutical company Sankyo in 1995. Olmesartan is administered as an ...

Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent ...

Please provide your email address to receive an email when new articles are posted on . LONDON — Elderly patients with systolic hypertension and suspected arterial stiffness had lower central systolic ...

Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. It is a prodrug that is ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Combination therapy with olmesartan and a calcium channel blocker was associated with similar ...

Endothelial dysfunction in essential hypertension is an independent predictor for future cardiovascular events. Although inhibition of the renin-angiotensin system (RAS) reportedly improves ...

Learn everything you need to know about Olmesartan-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The authors note that while the evidence points to a higher rate of enteropathy outcomes in patients treated with olmesartan, the absolute rate was found to be low. Patients treated with olmesartan ...